Notably, adiponectin has been associated with increased risk of respiratory mortality in COPD but is not significantly influenced by smoking status; thus, it is a very promising biomarker of cardiovascular outcomes in COPD [16]. Here, ADIPOQ is linked to chronic obstructive pulmonary disease.